Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer

Purpose. This randomized phase 2 study sought to assess the treatment effect of a finite duration of apalutamide with and without androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BCR PC). Materials and Methods. Patients with BCR PC after primary definitive therapy and p...

Full description

Bibliographic Details
Published in:	Prostate Cancer
Main Authors:	Rahul Aggarwal, Joshi J. Alumkal, Russell Z. Szmulewitz, Celestia S. Higano, Alan H. Bryce, Angela Lopez-Gitlitz, Sharon A. McCarthy, Branko Miladinovic, Kelly McQuarrie, Shibu Thomas, Ke Zhang, Eric J. Small
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Online Access:	http://dx.doi.org/10.1155/2022/5454727

Similar Items

Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
by: Takashi Ueda, et al.
Published: (2024-01-01)

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
by: Yongbao Wei, et al.
Published: (2023-10-01)

Apalutamide treatment and refractory hypothyroidism: effects of apalutamide on levothyroxine metabolism
by: Florie Quattrochi, et al.
Published: (2025-09-01)

Dermatological adverse events in Chinese prostate cancer patients treated with the androgen receptor inhibitor apalutamide
by: Qi Wang, et al.
Published: (2025-02-01)

Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial
by: Dingyuan Yang, et al.
Published: (2023-11-01)

Apalutamide-induced ichthyosiform eruption
by: Christian Ciolfi, et al.
Published: (2023-08-01)

A case of erythroderma caused by apalutamide
by: LIU Yan, et al.
Published: (2025-07-01)

Re: Final Report of the Intergroup Randomized Study of Combined AndrogenDeprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
by: Malcolm D. Mason, et al.
Published: (2015-06-01)

Early Identification and Management of Patients with Rash on Apalutamide
by: Alison J. Birtle, et al.
Published: (2024-08-01)

Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy
by: Beihe Wang, et al.
Published: (2024-05-01)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
by: Shimajiri Shohei, et al.
Published: (2011-05-01)

Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01)

Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy
by: Douglas G McNeel, et al.
Published: (2024-05-01)

Severe lichenified skin rash associated with apalutamide administration
by: Chisato Watanabe, et al.
Published: (2025-07-01)

Bioequivalence clinical trial simulation: a case study of apalutamide administered in applesauce versus whole tablets
by: Alex Yu, et al.
Published: (2023-08-01)

Treatment of Osteoporosis in Men on Androgen Deprivation Therapy in Japan
by: Hanako Nishimoto, et al.
Published: (2024-03-01)

A Case of Drug‐Induced Hypersensitivity Syndrome Caused by Apalutamide
by: Yuki Tanaka, et al.
Published: (2025-09-01)

Metabolic changes in patients with prostate cancer with androgen deprivation therapy
by: Maxim N. Peshkov, et al.
Published: (2020-06-01)

Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer
by: Laurence Klotz, et al.
Published: (2022-07-01)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
by: Kristene Myklak, et al.
Published: (2011-01-01)

Relationship between Androgen Deprivation Therapy and Abdominal Adipose Tissue
by: Federico Greco, et al.
Published: (2022-12-01)

Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial
by: Byung Ha Chung, et al.
Published: (2023-01-01)

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
by: Nora A. Alkhudair
Published: (2019-03-01)

Cutaneous Adverse Reactions to Apalutamide: Case Series with Clinical and Pathological Correlations
by: Javier Gil-Lianes, et al.
Published: (2024-09-01)

[Translated article] RF-Adverse Skin Reaction to Apalutamide: An Emerging Effect
by: M. Pons Benavent, et al.
Published: (2023-04-01)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
by: Gul A, et al.
Published: (2019-08-01)

Cost-effectiveness of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with highvolume, metastatic, hormone-sensitive prostate cancer
by: Huina Wu, et al.
Published: (2024-01-01)

Chlormadinone acetate is effective for hot flush during androgen deprivation therapy
by: Hidekazu Koike, et al.
Published: (2013-09-01)

Impact of androgen deprivation therapy on cognitive function in men with prostate cancer
by: Yutaka Yamamoto, et al.
Published: (2024-03-01)

Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.
by: Chi-Ho Lee, et al.
Published: (2017-01-01)

Microbial Endocrinology Redefines Prostate Cancer - The Bugs That Outwit Androgen Deprivation
by: Mohammad Asim
Published: (2025-07-01)

Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
by: Matthew E. Johnson, et al.
Published: (2012-01-01)

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer
by: Allison B. Reiss, et al.
Published: (2024-10-01)

Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
by: Safae Terrisse, et al.
Published: (2022-11-01)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
by: Per-Anders Abrahamsson
Published: (2017-10-01)

Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer
by: Shangwei Zhong, et al.
Published: (2022-02-01)

Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood
by: Allison B. Reiss, et al.
Published: (2023-12-01)

Influence of androgen deprivation therapy on glucose metabolism and ambulatory glucose profile
by: E. Yu. Grickevich, et al.
Published: (2021-05-01)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
by: Julia Lipianskaya, et al.
Published: (2014-08-01)

Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
by: Syed Imran Ali Shah
Published: (2015-01-01)